Value-based healthcare is rising, but is it making a difference?

Research shows that value-oriented payment systems are on the rise, with 40 cents of every healthcare dollar now tied in some way to value—up from only 11 cents one year ago, according to Forbes.

But is it improving quality and safety? The Leapfrog Group, which monitors both, has not found dramatic change consistant with the shifts in value-oriented payment now being reported, the article says.

Read more below:

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.